Loading…
Pharmasi+ (ფარმასი +) — despite the pharma-sounding name, this is a perfume/fragrance wholesale and retail business (analyst-confirmed), not a pharmaceutical company. Reclassified to Retail - Apparel & Specialty (Perfume & Cosmetics). Stable, healthy margins (~55%).
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross Margin | 53.1% | 57.6% | 58.9% | 57.1% | 56.2% | 52.6% |
| EBITDA Margin | 31.2% | 33.5% | 31.0% | 17.7% | 12.2% | 6.0% |
| EBITDAR | 1,228 | 1,283 | 1,522 | 717 | 465 | 229 |
| EBITDAR Margin | 32.4% | 34.0% | 31.7% | 18.7% | 13.2% | 7.3% |
| EBIT Margin | 31.1% | 33.3% | 30.5% | 16.7% | 11.0% | 4.5% |
| Net Profit Margin | 17.8% | 17.8% | 18.6% | 12.5% | 9.5% | 3.7% |
| Operating Expense % of Sales | 21.8% | 24.2% | 27.9% | 39.3% | 44.0% | 46.6% |
| Returns | ||||||
| Return on Assets (ROA) | 65.8% | 53.9% | 69.5% | 34.8% | 24.6% | 8.9% |
| Return on Equity (ROE) | 316.0% | 124.1% | 101.6% | 44.1% | 30.2% | 13.9% |
| ROIC [EBIT / Invested Capital] | 206.1% | 192.7% | 145.2% | 72.2% | 33.2% | 11.8% |
| Leverage & debt balances | ||||||
| Debt-to-Assets | 61.9% | 44.7% | 25.7% | 9.8% | 11.1% | 34.3% |
| Debt-to-Equity | 2.97x | 1.03x | 0.38x | 0.12x | 0.14x | 0.54x |
| Debt-to-EBITDA | 0.54x | 0.44x | 0.22x | 0.20x | 0.35x | 2.34x |
| Equity-to-Assets | 20.8% | 43.4% | 68.4% | 79.0% | 81.4% | 64.1% |
| Net Debt | 359 | 110 | 129 | -201 | 61 | 383 |
| Cash & Equivalents | 276 | 449 | 202 | 336 | 91 | 58 |
| Total Debt | 635 | 559 | 331 | 135 | 152 | 441 |
| Liquidity & working capital | ||||||
| Current Ratio | 1.29x | 15.80x | 2.38x | 3.90x | 4.22x | 2.04x |
| Quick Ratio | 0.42x | 14.83x | 2.38x | 3.90x | 4.22x | 2.04x |
| Cash Ratio | 0.36x | 0.64x | 0.50x | 1.16x | 0.36x | 0.13x |
| Total Current Assets | 1,000 | 11,163 | 968 | 1,132 | 1,071 | 943 |
| Total Current Liabilities | 775 | 707 | 407 | 290 | 254 | 462 |
| Inventory | 675 | 684 | N/A | N/A | N/A | N/A |
| Trade Receivables | 49 | 30 | 42 | 20 | 71 | 72 |
| Trade Payables | N/A | N/A | 10 | 72 | 75 | N/A |
| Net Working Capital | 225 | 10,457 | 561 | 842 | 817 | 481 |
| Net Working Capital % of Revenue | 5.9% | 276.8% | 11.7% | 22.0% | 23.2% | 15.3% |
| Trade Working Capital | 725 | 714 | 32 | -52 | -4 | 72 |
| Trade Working Capital % of Revenue | 19.1% | 18.9% | 0.7% | -1.4% | -0.1% | 2.3% |
| Change in Trade Working Capital | N/A | -10 | -682 | -84 | 49 | 76 |
| Turnover & efficiency | ||||||
| Inventory Turnover | 2.64x | 2.34x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | 138.5 | 156.1 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 77.19x | 125.97x | 115.01x | 194.79x | 49.65x | 43.58x |
| Days Sales Outstanding (DSO) | 4.7 | 2.9 | 3.2 | 1.9 | 7.4 | 8.4 |
| Payables Turnover | N/A | N/A | 203.38x | 22.88x | 20.69x | N/A |
| Days Payable Outstanding (DPO) | N/A | N/A | 1.8 | 16.0 | 17.6 | N/A |
| Cash Conversion Cycle | 143.2 days | 159.0 days | 1.4 days | -14.1 days | -10.3 days | 8.4 days |
| Asset Turnover | 3.70x | 3.02x | 3.73x | 2.78x | 2.59x | 2.44x |
| Cash flow & dividends | ||||||
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →